Kevin Church - May 18, 2021 Form 4/A - Amendment Insider Report for Athira Pharma, Inc. (ATHA)

Role
Vice President of Discovery
Signature
/s/ Glenna Mileson, Attorney in fact for Kevin Church
Stock symbol
ATHA
Transactions as of
May 18, 2021
Transactions value $
$5,951
Form type
4/A - Amendment
Date filed
6/10/2021, 06:41 PM
Date Of Original Report
Jun 9, 2021
Next filing
Jun 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Award $2.67K +185 +0.45% $14.45* 41.2K May 18, 2021 Direct F1, F2, F3
transaction ATHA Common Stock Options Exercise $3.28K +3.15K +7.66% $1.04 44.3K Jun 8, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Options Exercise $0 -3.15K -100% $0.00* 0 Jun 8, 2021 Common Stock 3.15K $1.04 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 filed on June 9, 2021 is being amended to voluntarily report the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of October 2, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c).
F2 The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began October 2, 2020.
F3 In accordance with the ESPP, these shares were purchased based on 85% of the initial public offering price from the issuer's initial public offering.
F4 The shares subject to the option fully vested on September 1, 2016.